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Abstract
Background
The Plasmodium vivax Reticulocyte Binding Protein (PvRBP) family is involved in red blood
cell recognition and members of this family are potential targets for antibodies that may
block P. vivax invasion. To date, the acquisition of immunity against PvRBPs in low malaria
transmission settings and in a broad age group of exposed individuals has not been
investigated.
Methodology/Principal findings
Total IgG antibody levels to six members of the PvRBP family (PvRBP1a, PvRBP1b,
PvRBP2a, PvRBP2b, a non-binding fragment of PvRBP2c (PvRBP2cNB) and PvRBP2-P2)
were measured in samples collected from individuals living in two regions of low P. vivax
endemicity in Brazil and Thailand. In both settings, levels of total IgG to PvRBP1a,
PvRBP2b, PvRBP2cNB, and PvRBP2P-2 increased significantly with age (rho = 0.17–0.49;
P<0.001). IgG responses to PvRBP1a, PvRBP2b and PvRBP2cNB were significantly higher
in infected individuals by using Wilcoxon’s signed-rank test (P<0.001). Of the six PvRBPs
examined, only antibodies to PvRBP2b were associated with protection against clinical
malaria in both settings.
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007596 August 19, 2019 1 / 17
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: He W-Q, Karl S, White MT, Nguitragool
W, Monteiro W, Kuehn A, et al. (2019) Antibodies
to Plasmodium vivax reticulocyte binding protein
2b are associated with protection against P. vivax
malaria in populations living in low malaria
transmission regions of Brazil and Thailand. PLoS
Negl Trop Dis 13(8): e0007596. https://doi.org/
10.1371/journal.pntd.0007596
Editor: Marcelo U. Ferreira, University of Sao
Paulo, BRAZIL
Received: October 1, 2018
Accepted: July 2, 2019
Published: August 19, 2019
Copyright: © 2019 He et al. This is an open access
article distributed under the terms of the Creative
Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in
any medium, provided the original author and
source are credited.
Data Availability Statement: Data available at
http://doi:10.5061/dryad.p678q83.
Funding: W.Q.H. is supported by both Melbourne
International Postgraduate Scholarship (MIPS) and
Melbourne International Research Scholarship
(MIRS), C.T.F is under the support of MIPS.
S.K. is supported by an NHMRC fellowship
(GNT1141441). M.V.G.L was supported by CNPq.
W.H.T. is a Howard Hughes Medical Institute-
Conclusion/Significance
Our results indicate that PvRBP2b warrants further preclinical development as a blood-
stage vaccine candidate against P. vivax. Total IgG responses to PvRBPs were also shown
to be promising immunological markers of exposure to P. vivax infection.
Author summary
Plasmodium vivax preferentially invades young red blood cells called reticulocytes. Suc-
cessful parasite invasion relies on the interaction between parasite ligands with human red
blood cell receptors. The P. vivax reticulocyte binding protein family (PvRBP) plays a role
in the invasion process. The role of PvRBP in the natural acquisition of immunity to
P. vivax, especially in low transmission settings, is poorly understood. Using samples from
longitudinal cohort studies from regions of low P. vivax endemicity in Brazil and Thai-
land, we showed that antibody responses to PvRBP1a, PvRBP2b, and PvRBP2cNB
increased with age and were boosted during infection. In addition, higher antibody levels
to PvRBP2b were strongly associated with a lower risk of clinical episodes of P. vivax.
Based on these observations, we propose that PvRBP2b warrants further preclinical devel-
opment as a blood-stage vaccine candidate against P. vivax.
Introduction
Plasmodium vivax is the most widespread human malaria parasite species [1]. Although 4% of
estimated cases globally are caused by P. vivax, this proportion is 36% outside the African con-
tinent [2]. The majority of P. vivax infection occurs in the South-East Asia Region, which
accounts for 58% of cases worldwide [2]. P. vivax accounts for more than 30% of total malaria
cases in South-East Asia and 64% in the Americas. In some countries, such as Thailand and
Brazil, P. vivax infection is responsible for 80% and 90% of malaria cases respectively [2]. As
many countries progress towards the malaria elimination, P. vivax infection has emerged as
one of the key challenges [3]. This is likely to be related to several biological and epidemiologi-
cal characteristics of P. vivax. First, P. vivax infections typically exhibit low levels of blood-
stage parasitemia, thus reducing the proportion of infections detected by light microscopy and
rapid diagnostic tests. Furthermore, compared to P. falciparum, P. vivax develops in a wider
temperature range [4]; and transmissible gametocytes emerge earlier in the blood circulation
(frequently before the development of clinical symptoms), making this parasite highly trans-
missible [5]. Last but not least, P. vivax forms hypnozoites in the liver [6,7], which can
reactivate weeks to months after the initial infection resulting in relapses. Hypnozoites are
undetectable by any current diagnostic assay [5] but are the cause for the majority of relapsing
P. vivax blood-stage infections [8]. In highly endemic regions, children acquire clinical immu-
nity to P. vivax at a younger age compared to P. falciparum, leading to protection from clinical
disease before adolescence [9]. In low-transmission settings reduced exposure leads to all age
groups being at risk of clinical P. vivax illness [9].
Invasion of red blood cells by Plasmodium merozoites depends on specific interactions
between parasite ligands and red blood cell receptors [10]. P. vivax preferentially invades young
red blood cells called reticulocytes. In particular, P. vivax prefers to invade reticulocytes with
high levels of transferrin receptor 1 (TfR1 or CD71) [11]. To date, there are two known families
of parasite adhesins that bind red blood cells: the P. vivax Duffy binding protein family (PvDBP)
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and the P. vivax reticulocyte binding protein family (PvRBP). The PvDBP family has at least
three members: PvDBP, PvDBP2, and P. vivax erythrocyte binding protein (PvEBP) [12,13].
The PvRBP family has at least 11 members, encoded in three partial genes and eight full-length
genes [12,14]. Analyses of the red blood cell binding specificity of native and recombinant frag-
ments of PvRBP proteins show that different members of this protein family exhibit different
binding preferences for normocytes and/or reticulocytes [15–19]. The crystal structures of the
N-terminal domains of PvRBP2a and PvRBP2b have been recently determined, revealing a simi-
lar structural scaffold to that of P. falciparum reticulocyte-binding protein homolog 5 (PfRh5)
[20–22], one of the leading vaccine candidates for P. falciparum blood stages [23].
The first receptor identified for P. vivax invasion was the Duffy Antigen Receptor for Che-
mokines (DARC) which binds to P. vivax PvDBP [24]. Historically, PvDBP-DARC binding
was thought to be the main interaction for P. vivax invasion [25], but the identification of P.
vivax infection in Duffy-negative patients suggest the presence of alternative invasion path-
ways [26]. Recent studies show that PvRBP2b binds to transferrin receptor 1 (TfR1) to mediate
a critical invasion pathway for entry into reticulocytes [21,27]. Mouse monoclonal antibodies
raised against PvRBP2b abolished the PvRBP2b binding to reticulocytes and inhibit P. vivax
entry into reticulocytes [21]. These observations highlight the value of PvRBP2b as a potential
vaccine candidate for P. vivax.
Whole genome sequence of P. vivax Salvador I has identified 10 PvRBP genes, and they are
named as PvRBP1a, PvRBP1b, PvRBP1 (Partial), PvRBP2a, PvRBP2b, PvRBP2c, PvRBP2-P1,
PvRBP2-P2, PvRBP2d, and PvRBP3 [14]. Genetic diversity of PvRBP1a is markedly lower than
that of PvRBP2c from parasite isolates originating from Brazil and Thailand [28]. High diver-
sity of PvRBP2a was observed among 31 P. vivax isolates, which includes 22 isolates from
PNG, four from Thailand, and five reference strains [20]. The highest nucleotide diversity is
concentrated in the first 2.2 kb with evidence of significant balancing selection in this region
[20]. Genetic variation of PvRBP2b has been analyzed using 148 P. vivax samples in the Malar-
iaGEN P. vivax Genome Variation project [21,29]. Balancing selection was observed within
the N-terminal domain at amino acid positions 169 to 470 [21]. Signatures of balancing selec-
tion may be linked to genes encoding surface exposed-proteins of the invasive blood-stage
merozoite [30], suggesting the possibility that PvRBPs are targets of immunity.
Several studies have examined different aspects of naturally acquired immunity to PvRBPs
[16,18,31–33]. Immunoreactivity to five recombinant fragments of PvRBP1a was determined
among 297 donors from three communities of Rondoˆnia, a state in the western Amazon region
of Brazil where P. vivax accounts for 70% of all malaria cases [31]. These results show that IgG
responses towards these recombinant PvRBP1a fragments were age-independent but exposure-
dependent. The positive correlation between IgG to PvRBP1a and previous malaria exposure
was further supported by another study on 253 individuals from the same region [32]. In a sep-
arate study in Thailand, IgG levels to five different PvRBPs and their associations with age and
parasitemia were investigated in 41 plasma samples from P. vivax infected adult patients [33].
Antibodies to all five PvRBPs increased with age and a negative correlation with P. vivax parasi-
temia was observed for antibody responses to PvRBP2b [33]. A study performed with 104
residents of the Republic of Korea showed no significant associations were found between
humoral immune responses to PvRBP1a and PvRBP1b and parasitemia [18]. Collectively,
these cross-sectional studies included only limited clinical information thus the association of
immune responses to PvRBPs with risk of clinical P. vivax malaria can not be determined.
A recent study in a well-characterized longitudinal cohort of young children (1–3 years old)
from an area of high malaria endemicity in Papua New Guinea (PNG) showed that antibodies
to PvRBP1a and PvRBP2b were strongly associated with reduced risk of clinical malaria epi-
sodes as defined by fever plus parasitemia >500/μL [16]. A full understanding of the
Protective association of IgG to PvRBP2b with malaria in low transmission areas
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007596 August 19, 2019 3 / 17
development of immune responses to PvRBPs in older populations and those living in areas of
low endemic settings is still lacking. To better understand the development of immunity to
PvRBPs, it is important to determine if protective immunity develops in regions of low
P. vivax transmission or whether infections occur too infrequently to allow the development of
protective immunity. In this study, we investigated the association of antibody responses to six
PvRBPs with age, infection status, malaria exposure and clinical episodes in samples collected
in Brazil and Thailand in 2013. Our results show that naturally acquired immunity to PvRBP2b
could serve as a valuable correlate of protective immunity against clinical P. vivax episodes in
all age groups from low transmission intensity settings.
Methods
Ethical statement
Ethics approvals were obtained from the Ethics Committee of the Faculty of Tropical Medi-
cine, Mahidol University (MUTM 2013-027-01) and the Fundac¸ão de Medicina Tropical Dou-
tor Heitor Vieira Dourado (349.211/2013).
Cohort studies
Plasma samples used in the current study were collected as part of two longitudinal cohort
studies conducted in Brazil and Thailand. The study in Brazil was undertaken in the villages of
Brasileirinho, Puraquequara, and Ipiranga located in peri-urban areas of Manaus in April 2013
to May 2014 and included a total of 1274 participants of age ranges from 4 days to 102 years
(Monteiro, Karl et al., in preparation). The study in Thailand was undertaken in the provinces
of Kanchanaburi and Ratchaburi in May 2013 to June 2014 and included 1000 individuals aged
from 1 to 82 years [34]. The two studies had a similar longitudinal design. In brief, participants
were followed for 12 months and screened at monthly intervals for symptomatic illness and
infection status as detected by PCR. All P. vivax infections were genotyped using PCR, allowing
for the calculation of the incidence of genetically distinct blood-stage infections during follow-
up (i.e., the molecular force of blood-stage infections, molFOB) as previously described [35].
Plasma samples collected at the start of these studies were used for antibody measurement.
Expression and purification of recombinant PvRBPs
The six PvRBPs used in this study were PvRBP1a (amino acid [aa] 160–1170), PvRBP1b (aa
140–1275), PvRBP2a (aa 160–1135), PvRBP2b (aa 161–1454), PvRBP2c Non-Binding
(PvRBP2cNB, aa 501–1300) and PvRBP2P-2 (aa 161–641). Their accession numbers are
PVX_098585, PVX_098582.1, PVX_121920, PVX_094255, PVX_090325, and PVX_101590,
respectively (www.plasmodb.org/plasmo). Methods for protein expression and purification of
have been described elsewhere [20,21].
PvRBP conjugation and measurement of IgG responses
Conjugation of recombinant PvRBPs to Luminex 5.6 polystyrene microspheres was performed
as previously described [36]. The corresponding concentrations of each of the six PvRBP con-
structs used to conjugate 2.5 x 106 microspheres were as follows: PvRBP1a = 3.0 μg/mL;
PvRBP1b = 11.4 μg/mL; PvRBP2a = 6.7 μg/mL; PvRBP2b = 0.2 μg/mL; PvRBP2cNB = 0.8 μg/
mL; PvRBP2-P2 = 5.4μg/mL.
The multiplex antibody detection assay was performed as described elsewhere [16,36].
Briefly, plasma samples were diluted into 1:100 in phosphate-buffered saline containing 1%
bovine serum albumin and 0.05% Tween. Samples were incubated with the conjugated beads
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(1:50 ratio) for 30 minutes under constant agitation. PE-conjugated donkey anti-human IgG
fragment crystallisable region (Fc) was used as the secondary antibody in a volume of 100 μL/
well at 1 μg/mL. Beads were read on a Bio-Plex200 reader. Results are reported as median fluo-
rescence intensity (MFI). A blank well without plasma was included for determination of the
true fluorescence background. As immune responses to pooled serum (from highly malaria
exposed Papuan New Guinean adults (>18 years) from the Madang (n = 10) and East Sepik
Provinces (n = 10)) are very strong, in each batch, a twofold serial dilution from 1/50 to 1/
25,600 of this pool was included to generate a standard curve to minimize the variation from
different plates.
Statistical analyses
Specific standard curves from each Luminex assay plate were used for transformation of MFIs
into relative antibody units (expressed as dilution factors that range from 1.95 x 10−5 or 1/51200
to 0.02 or 1/50) using a five parametric logistic regression model as described previously [16].
Statistical analyses were performed using STATA version 12 (StataCorp) and R version
3.2.1 (htpp://cran.r-project.org). LOESS smoothing with 95% prediction interval was applied
to plot antibody levels in relation to age. Spearman’s rank correlation was used to assess associ-
ations between antibody levels and age and correlations among antibody responses against dif-
ferent antigens. The differences in antibody levels between categorical variables were assessed
using Unpaired Two-Sample Wilcoxon’s Signed-Rank Test. Differences in the mean and pro-
portions of population demography were evaluated by t-test and chi-square test. Multivariable
logistic regression was used to investigate the association of current infection and infection in
the follow-up periods with antibody responses, including the following variable as covariates
for both studies: age, molFOB, gender and pregnancy, where gender and pregnancy were
combined into a categorical variable as below: non-pregnant female (reference group), preg-
nant female and male. As the Thai cohort was conducted on the border of Thailand and Myan-
mar—where cases are known to often be introduced from Myanmar, we also included the
proportion of indoor-spraying and sleeping in Myanmar as covariates for the Thai cohort
analyses. Receiver operating characteristics (ROC) curves were applied to determine the rela-
tive accuracy of antibody responses to each PvRBPs to predict current infection. Overall accu-
racy of each antigen to predict current infection was quantified as area under the curves
(AUCs). AUCs were calculated on a threshold basis: if an individual’s baseline antibody levels
were higher than a particular threshold, then that individual was classified as having concur-
rent infection. Cox proportional hazards models were used to investigate associations between
antibody responses and time to first clinical episode. For this, a clinical episode was defined as
the presence of axillary temperature�37.5˚C or fever in the last 48 hours in the presence of
any P. vivax density by light microscopy [37]. Antibody levels were divided into higher and
lower groups based on the median values for the corresponding antigens and Kaplan-Meier
estimates were computed until endpoints of the longitudinal cohort study were reached. Log-
rank tests were used to explore the differences between survival curves.
All datasets were available in the Dryad repository: http://doi:10.5061/dryad.p678q83 [38].
Results
Demography of the study population and acquisition of antibodies to
PvRBPs in Brazilian and Thai cohort studies
The prevalence of P. vivax infection by PCR at baseline for the Brazilian and Thai cohorts was
3.4% (39/1163, 95% CI 2.5%-4.6%) and 2.9% (28/973, 95% CI 2.0%-4.1%) respectively.
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Baseline characteristics of the study participants with infection are shown in S1 Table. In the
Brazilian study, older individuals had higher risk of P. vivax infection (P = 0.035). Pregnant
women were also more likely to have P. vivax infection (P = 0.004). In comparison with the
general female population, males were more likely to be infected with P. vivax although only
borderline significance was observed (P = 0.085). The participants with higher molFOB values
were more likely to have infection (P<0.001). For the Thai study, participants with higher mol-
FOB values, and males were more likely to be infected with P. vivax (P�0.006). The age distri-
bution and proportion of the population using insecticide-treated bed nets were similar for the
two groups in both two studies (P = 0.148–0.789). The individuals who had travelled and
stayed over night in in Myanmar was significantly higher in the infected population than in
the non-infected population (P<0.001). On the other had, participants benefited from indoor
spraying as a higher proportion of population in the uninfected group use this control strategy
(P = 0.049).
In this study, we used pooled plasma from immune PNG adults as a positive control and
determined the number of study participants with IgG levels equivalent to>50%, >25%,
>10%, >5%, or >1% of PNG adults’ IgG levels for both uninfected individuals and those with
P. vivax infection during the period of the longitudinal study (Fig 1A and 1C, S2 Table). For
antibody responses to PvRBP1a, PvRBP2b, and PvRBP2cNB in both studies, the prevalence of
individuals with>1%, >5%, 10%, >25% and >50% of immune PNG adult levels among indi-
viduals with any infection were also higher than those without any infection (Fig 1A and 1C,
S2 Table). The geometric mean antibody levels of participants with any P. vivax infection were
higher than participants without any infection for the three antigens (P<0.001) (Fig 1B and
1D, S2 Table). Overall, apart from antibody levels of PvRBP2cNB (P = 0.137), Brazilian partici-
pants had higher antibody levels than Thai participants (P�0.002), with the exception of anti-
body levels to PvRBP2cNB (P = 0.137).
Total IgG in relation to age, infection and molFOB
The correlations of antibody responses to the six PvRBPs and age were determined. Levels of
antibodies to PvRBP1a, PvRBP2b, PvRBP2cNB, and PvRBP2P-2 increased with age in both
Brazilian and Thai studies (rho = 0.09–0.49; P�0.005, Fig 2).
Individuals with concurrent P. vivax infection by PCR at baseline (n = 39 in the Brazilian
study; n = 28 in the Thai study) had significantly higher antibody levels to PvRBP1a, PvRBP2b,
and PvRBP2cNB (P<0.001) (Fig 3).
Antibodies to PvRBP2b showed the strongest association with likelihood of infection in
both studies for our unadjusted and adjusted analysis (Fig 4). For each unit increase in anti-
body levels (one log10-transformed antibody unit), it was associated with about 4-fold
(muOR = 4.17, IC95 [2.54–7.23], P< 0.001) and 5-fold (muOR = 5.26, IC95 [2.63–11.39],
P< 0.001) increase in the odds of being infected in the Brazilian and Thai studies, respectively.
The accuracy of these predictions was further confirmed by receiver operating characteristic
analyses, with AUC PvRBP2b being the highest for the prediction of concurrent infection
(AUC = 0.824–0.865), followed by PvRBP1a (AUC = 0.713–0.733) and PvRBP2cNB (AUC =
0.695–0.784) (S1 Fig).
To investigate the association of antibody responses to six PvRBP and risk of infection in
the follow-up periods, we evaluated the association between antibody levels at enrolment
and the risk of P. vivax infections over the 12 months of follow-up. In both studies, in the par-
ticipants free of infection at enrolment, antibody responses to PvRBP1a, PvRBP2b, and
PvRBP2cNB (and those to PvRBP2a in the Brazilian cohort only) were strongly associated
with increased risk of infection over the study preriod for both unadjusted and asjusted models
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(P�0.002, Fig 5). No difference was observed for individuals with infection at enrolment
(Fig 5).
Antibody responses to PvRBP2b predict reduced incidence of symptomatic
malaria
For the Brazilian and Thai cohorts, a low burden of P. vivax disease was observed during fol-
low-up, with only 6.4% (75/1163) and 2.6% (25/973) of participants experiencing at least one
symptomatic episode of P. vivax malaria, respectively. In order to determine the association
of antibody levels with protection against clinical episodes, we restricted our analyses to
Fig 1. Antibody levels of Brazilian and Thai cohort studies in comparison with antibody levels of PNG adults. The comparisons of proportions of
participants with IgG levels equivalent to>1%,>5%,>10%,>25%, and>50% of PNG adults levels between the uninfected individuals and those suffered any
P. vivax infection for the longitudinal study periods were shown in A (Brazilian study) and C (Thai study). The empty bars represented the proportions of
uninfected individuals and the filled bars displayed the proportions of individuals with any infection for each level (>1%,>5%,>10%,>25%, and>50%).
Figure B and D showed the comparison of antibody levels between the uninfected and infected population for each antigen in the two cohort studies. Data were
geometric mean with 95% confidence interval. IgG levels multiplied by 1000. The blank bars were the population without infection for the studies (n = 235 and
n = 80 in Brazilian and Thai cohorts, respectively) and filled bars were those with any infection (n = 928 and n = 893 in Brazilian and Thai cohorts, respectively).
�P<0.001 for the comparison of the two groups for antibody levels to each PvRBPs.
https://doi.org/10.1371/journal.pntd.0007596.g001
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individuals with at least one infection during follow-up (Table 1), of which 31.8% (75/236) of
the Brazilian and 31.6% (25/79) of the Thai cohorts experienced at least one symptomatic epi-
sode. Individuals were divided into high and low responder groups by median levels of IgG
corresponding to each antigen. By using Kaplan Meier curves and log-rank test, in the Brazil-
ian cohort, high responders to all PvRBPs except for PvRBP1b showed significantly longer
time to develop symptomatic disease as compared to low responders (P� 0.002, Fig 6). In the
Thai study, participants with higher antibody levels to PvRBP2b and PvRBP2cNB were also
more likely to remain free of clinical episodes for longer periods than low responders
(P�0.002, Fig 6).
Using Cox proportional hazards model, two separate models were tested by including
age and other potential confounders (Table 1). Antibody responses to all the six antigens
were significantly associated with reduced risk of clinical P. vivax malaria in the Brazilian
study (age+expHR = 0.25–0.59, P�0.031, Table 1). In contrast, a protective association was only
identified for PvRBP2b in the model adjusting age and other exposure variables in the Thai
study (age+expHR = 0.50, IC95 [0.27–0.94], P = 0.031). In addition, our multivariable model
including antibodies univariately associated with protection revealed that revealed only anti-
body levels to PvRBP2b were associated with protection for both cohorts by using stepwise
backwards selection (for Brazilian study: muHR = 0.43, IC95 [0.32–0.58], P<0.001; for Thai
study: muHR = 0.50, IC95 [0.26–0.94], P = 0.032, Table 1). These results suggested that the
Fig 2. Antibody levels of IgG to six PvRBPs in relation to age. The top and bottom panels represent total IgG levels to six PvRBPs in relation to age of Brazilian
and Thai participants, respectively. The line shows the LOESS smoothed estimate of the log10 transformed arbitrary unit (AU) and shaded regions represent 95%
prediction interval. The black dots in the background represented the raw data. The Y-axis represents antibody levels in log10 transformed arbitrary units and the
x-axis represents the age of participants.
https://doi.org/10.1371/journal.pntd.0007596.g002
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significant association in the univariate model might be due to the strong correlation between
PvRBP2b with other PvRBPs in Brazilian study (rho = 0.47–0.77, Table 2) and the correlation
between antibody responses to PvRBP2b and PvRBP2cNB (rho = 0.76) in Thai study.
Discussion
In this study, we characterized the association between IgG responses to six PvRBPs with
P. vivax infection and clinical episodes in regions of low P. vivax endemicity in Brazil and
Thailand. Our results suggest that IgG responses to PvRBP1a, PvRBP2b, and PvRBP2cNB
could be immunological markers of asymptomatic P. vivax infection in these malaria low
transmission areas. Furthermore, antibody levels to PvRBP2b showed strong association with
protective immunity against clinical P. vivax episodes.
It has been reported that acquired clinical immunity to P. vivax malaria depends on
repeated exposure to infection [39]. Asymptomatic infections seem to have boosted the total
IgG antibody levels to PvRBP1a, PvRBP2b, and PvRBP2cNB. Both Brazilian and Thai study
Fig 3. Distribution of antibody levels of PvRBPs and comparison of antibody levels between PCR positive and negative P. vivax population. Probability
density functions were plotted in the figure divided by infection status, in which red refers to individuals without infection and blue refers to individuals with
infection population (39 in Brazilian and 28 in Thai study). Y-axis represents density of abundance of antibody responses, x-axis represents levels of antibody
responses; sample size (1163 in Brazilian and 973 in Thai study); P value for assessing significant differences between antibody levels in the PCR negative and PCR
positive groups were calculated using Unpaired Two-Sample Wilcoxon’s Signed-Rank Test. P<0.001 in both cohorts for PvRBP1a, PvRBP2b and PvRBP2cNB.
https://doi.org/10.1371/journal.pntd.0007596.g003
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sites showed that antibody levels to these antigens increased throughout childhood and into
adulthood, supporting the premise that antibodies to PvRBPs are a strong reflection of both
concurrent and past exposures to P. vivax infections. In both Brazil and Thailand, we did not
observe any association of antibody levels against PvRBP1b with age or cumulative exposure.
However, antibody responses to PvRBP1b were associated with age and cumulative exposure
in the young PNG children [16]. This is likely a result of the high transmission intensity in the
PNG paediatric cohort, in which each child on average had acquired 14 new P. vivax blood-
stage infections per year [35]. In our study, the prevalence of infection was only about 3%,
which was reflected in the lower antibody levels to PvRBPs observed in both the Brazilian and
Thai population in comparison to PNG children [16].
molFOB estimates the number of distinct P. vivax clones acquired over the course of the fol-
low-up period and is thus a direct measure of the individual heterogeneity in exposure to P.
vivax [35]. A previous study indicates that molFOB is an important predictor of clinical disease
and a surrogate marker of malaria transmission [40]. Consistent with previous findings from
PNG children living in a highly endemic P. vivax transmission region [16], we identified
strong associations of antibody responses to PvRBP1a, PvRBP2b, PvRBP2cNB and infection in
the follow-up periods in participants without concurrent infection. The boost in antibody lev-
els by an active infection may have obscured similar associations in infected individuals. Nev-
ertheless, our results suggest that antibody responses to PvRBP1a, PvRBP2b, and PvRBP2cNB
may not only be markers of recent past infections but could potentially be used to predict the
individuals with the highest prospective risk of blood-stage infections. Further studies are nec-
essary to investigate the longevity of antibodies to PvRBPs.
The only longitudinal study to characterize the association between antibody responses to
PvRBPs and clinical infection was conducted in a highly endemic area of PNG, showing that
antibodies to PvRBP1a and PvRBP2b are strongly associated with reduced risk of clinical epi-
sodes among young children [16]. Our study with participants of all ages from a low P. vivax
Fig 4. Associations of antibody responses to the six PvRBPs with concurrent infection of P. vivax. A logistic regression model was used to estimate the odds of a
concurrent infection with every log rise in antibody levels. For the age adjusted model, only age was included as a covariate while for the age and exposure adjusted
model (shown as muOR), the variables were included as below: age, sex, pregnancy, molFOB for both studies, and also the proportion sleeping in Myanmar and
proportion of indoor spray in Thai cohort. The squares represent odds ratios (ORs) and the horizontal lines depict corresponding 95% confidence interval (CI).
ORs>1 indicate that antibody responses are associated with increased risk of infection whereas ORs<1 indicate lower risk of infection. The ORs equal to 1 for the
vertical line, which means there is no difference for the compared two groups. Abbreviations: OR, odds ratio; CI, confidence interval; aOR, age adjusted odds ratio;
muOR, multivariable adjusted odds ratio.
https://doi.org/10.1371/journal.pntd.0007596.g004
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transmission setting enabled us to explore whether antibodies to PvRBPs were biomarkers of
protective immunity in a broader age range. Antibody responses to PvRBP2b were consistently
found to be strongly associated with protection in both cohorts. Although the significant pro-
tective associations with PvRBP2cNB were also found in both cohorts, PvRBP2cNB is a recom-
binant protein that does not include the functional binding domain. Therefore, the protective
association with PvRBP2cNB is unlikely to be functional but could be due to the high correla-
tion of antibody responses with PvRBP2b (rho = 0.76–0.77 P<0.001). Adjusting our statistical
models for antibody levels to PvRBP2b completely accounted the for the protective association
observed for PvRBP2cNB. Therefore, it is likely that the antibody response to PvRBP2cNB is a
biomarker of immune status.
The TfR1-PvRBP2b invasion pathway is critical for P. vivax invasion into reticulocytes
and monoclonal antibodies against PvRBP2b that block recombinant PvRBP2b binding to
Fig 5. Associations of antibody responses to the six PvRBPs with following infections of P. vivax over the follow-up periods. A logistic regression model was
used to estimate the odds of a following infection with every log rise in antibody levels. For the age adjusted model, only age was included as a covariate while for
the age and exposure adjusted model, the variables were included as below: age, sex, pregnancy, molFOB, for both studies, and also the proportion sleeping in
Myanmar and proportion of indoor spray in the Thai cohort. The above model was stratified by the baseline infection status. The squares represent coefficient and
the horizontal lines depict corresponding 95% confidence interval. ORs>1 indicates that antibody responses are associated with increased risk of infection whereas
ORs<1 indicates lower risk of infection. ORs equals to 1 for a vertical line. Abbreviations: OR, odds ratio; CI, confidence interval; aOR, age adjusted odds ratio;
muOR, multivariable adjusted odds ratio.
https://doi.org/10.1371/journal.pntd.0007596.g005
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reticulocytes inhibit P. vivax invasion [21,27]. Given the very strong association of naturally
acquired antibody responses to PvRBP2b with protection in Brazil, Thailand and PNG [16,41],
it is likely that PvRBP2b antibodies are a functionally important aspect of naturally acquired
anti-P. vivax immunity. As a consequence, PvRBP2b should be considered as a target for fur-
ther development as a potential vaccine candidate.
Table 1. Association between antibodies responses to PvRBPs and risk of clinical malaria.
Study Antigen Age-adjusted analysis Exposed-adjusted analysis Multivariate analysis
aHR� (95% CI) P value age+expHR�� (95% CI) P value muHR��� (95% CI) P value
Brazilian study PvRBP1a 0.47 (0.31, 0.7) <0.001 0.47 (0.31, 0.70) <0.001
PvRBP1b 0.58 (0.36, 0.94) 0.156 0.59 (0.37, 0.95) 0.180
PvRBP2a 0.45 (0.31, 0.67) <0.001 0.45 (0.30, 0.67) <0.001
PvRBP2b 0.44 (0.33, 0.59) <0.001 0.43 (0.32, 0.58) <0.001 0.43 (0.32, 0.58) <0.001
PvRBP2cNB 0.51 (0.36, 0.71) <0.001 0.50 (0.36, 0.70) <0.001
PvRBP2P-2 0.27 (0.14, 0.53) <0.001 0.25 (0.13, 0.51) <0.001
Thai study PvRBP1a 0.51 (0.25, 1.00) 0.312 0.73 (0.35, 1.49) 1.000
PvRBP1b 1.42 (0.79, 2.55) 1.000 1.41 (0.70, 2.83) 1.000
PvRBP2a 0.95 (0.49, 1.83) 1.000 1.13 (0.52, 2.43) 1.000
PvRBP2b 0.34 (0.21, 0.55) <0.001 0.50 (0.26, 0.94) 0.186 0.50 (0.26, 0.94) 0.031
PvRBP2cNB 0.50 (0.30, 0.81) 0.030 0.65 (0.34, 1.24) 1.000
PvRBP2P-2 0.51 (0.16, 1.59) 1.000 0.65 (0.21, 2.02) 1.000
Note. Antibodies levels were categorized into high and low responders by median levels to each detected antigen. Hazards ratio (HR) was obtained by using Cox
proportional hazards model to compute the hazards between higher and lower groups. Only 236 and 79 participants from Brazil and Thailand studies were involved in
the above analysis, of which 31.8% (75/236) and 31.6% (25/79) experienced a first symptomatic episode. Abbreviation: HR = hazard ratio; aHR = adjusted hazard ratio;
muHR = multivariable adjusted hazard ratio.
�Adjustment for the age of participants.
��Adjustment for individual differences in exposure (molFOB), age, gender, and pregnancy for both studies, as well as the proportion of sleep in Myanmar and
proportion of indoor spray in the Thai study. P values was corrected by multiplying a factor of 6.
���Multivariable analysis of antibodies univariately associated with protection by using stepwise backward selection with P value 0.05 as cutoff. Symptomatic P. vivax
episode was defined as the presence of axillary temperature�37.5˚C or fever in the last 48 hours in the presence of any P. vivax density by light microscopy.
https://doi.org/10.1371/journal.pntd.0007596.t001
Fig 6. The association of antibody responses to PvRBPs and time to first P. vivax clinical episode. Kaplan-Meier curves showed time to first P. vivax clinical
episode for total IgG responses against six PvRBPs in Brazilian and Thai studies. Antibody responses were equally divided into two groups: high (red line) and low
(blue line) antibody reactivity, with a log-rank test to analyze the differences between every two groups. Only individuals experienced at least one asymptomatic
infection during follow-up were involved in this analysis. Symptomatic P. vivax episode was defined as the presence of axillary temperature�37.5˚C or fever in the
last 48 hours in the presence of any P. vivax density by light microscopy.
https://doi.org/10.1371/journal.pntd.0007596.g006
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There is a large body of evidence suggesting that protection against malaria is dependent on
high levels of antibody concentrations [42]. Direct comparison of antibody levels to the same
P. falciparum antigens between two cohorts of PNG 1–3 years old and 5–14 school-aged chil-
dren indicated that a threshold level of antibodies might be required to be involved in protec-
tive immunity [42], in which IgG responses were substantially higher in the older cohort. The
relatively low prevalence of P. vivax infections in our study (around 3% in both cohorts) may
indicate a transmission level that may be too low to boost the residents immunity and indeed,
compared to PNG adults, both Thai and Brazilian participants had low antibody titres. How-
ever, immune serum from participants with infection as determined by PCR in the study peri-
ods from Thailand and Brazil revealed a significant association of antibodies to PvRBP2b with
clinical protection. The strength of the association with protection against clinical malaria was
similar to that observed for PvRBP2b in the PNG children aged 1–3 years [16]. Collectively,
these results show that relatively low levels of antibody to PvRBP2b may be sufficient for
protection.
In summary, we showed that antibody responses to PvRBP1a, PvRBP2b, and PvRBP2cNB
are suitable immunologic markers of exposure to P. vivax infection in malaria low-transmis-
sion settings and IgG responses to PvRBP2b are likely to protect the population against further
clinical episodes. Further studies which include functional assays and antibody longevity mea-
surements will be necessary to assess the potential of PvRBP2b as a vaccine candidate and to
estimate the other PvRBPs as markers of exposure and/ or immunity.
Supporting information
S1 Fig. Receiver operator characteristics curves for antibody levels of PvRBPs to deter-
mine the risk of concurrent infection. (A) Antibody response to PvRBPs in Brazilian study.
(B) Antibody response to PvRBPs in Thai study. Abbreviation: AUC = area under curve.
(TIF)
S1 Table. Baseline characteristics of the study participants with infection. Note. For contin-
uous quantities, Student t test was used to test for differences between the means of the groups,
while chi-square test was performed to analyze the proportion differences of binary variables.
Table 2. Correlation between antibody responses to PvRBPs in the two cohort studies.
Study Antigen Correlation coefficient
PvRBP1a PvRBP1b PvRBP2a PvRBP2b PvRBP2cNB PvRBP2P-2
Brazil study PvRBP1a 1.00
PvRBP1b 0.37 1.00
PvRBP2a 0.62 0.77 1.00
PvRBP2b 0.65 0.47 0.77 1.00
PvRBP2cNB 0.64 0.52 0.79 0.77 1.00
PvRBP2P-2 0.42 0.73 0.66 0.50 0.54 1.00
Thailand study PvRBP1a 1.00
PvRBP1b 0.33 1.00
PvRBP2a 0.51 0.88 1.00
PvRBP2b 0.59 0.35 0.52 1.00
PvRBP2cNB 0.64 0.39 0.58 0.76 1.00
PvRBP2P-2 0.40 0.52 0.56 0.43 0.45 1.00
Note. Correlation coefficient was determined by Spearman’s method. All P values was corrected by multiplying a factor of 6. All correlations are significant at a
corrected P value of <0.001.
https://doi.org/10.1371/journal.pntd.0007596.t002
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P<0.05 was deemed significant. Abbreviation: molFOB = the molecular force of blood-stage
infection.
(XLSX)
S2 Table. Antibody levels of Brazilian and Thai cohort studies in comparison with anti-
body levels of PNG adults. Abbreviations: No = number, geom mean = Geometric mean,
95% CI = 95% confidence interval. �IgG levels multiplied by 1000. Values are in relative anti-
body units interpolated from standard curves using a 5PL logistic regression model.
(XLSX)
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